Mothers’ Obesity May Pre-Program Children for Obesity, Metabolic Disease
Children may have a higher risk for fat accumulation and insulin resistance if their mothers were obese.
ADA 75th Scientific Sessions 2015
Food Insecurity Affects Diabetes Control in Latino Patients
Food insecurity has an impact on glycemic control and vegetable consumption in Latino patients with diabetes.
GLP-1 May Modify Brain’s Response to Food
Gut-based medications like GLP-1 agonists may induce weight loss by reducing cravings and increasing satiety.
FLAT-SUGAR: GLP-1 Agonist Reduced Glycemic Variability Without Changing HbA1c
GLP-1 receptor agonist may be able to reduce glycemic variability rather than a prandial insulin.
TECOS: Sitagliptin Not Linked to Increased CV Risk, Heart Failure
Sitagliptin did not affect rates of cardiovascular complications or heart failure in high-risk patients with type 2 diabetes.
ELIXA: No Cardiac Risks, Benefits With Lixisenatide
Lixisenatide has neutral effect on heart failure and other cardiovascular outcomes.
ITCA 650 Safe, Effective in Type 2 Diabetes
ITCA 650, which continuously delivers exenatide subcutaneously, yielded improvements in HbA1c and body weight in patients with type 2 diabetes.
Dulaglutide Beat Insulin Glargine in Type 2 Diabetes
Compared with insulin glargine, once-weekly dulaglutide led to superior reductions in HbA1c in patients with type 2 diabetes.
Basal Insulin Peglispro vs. Insulin Glargine in Type 1 Diabetes
People with type 1 diabetes treated with basal insulin peglispro vs. insulin glargine had significantly lower HbA1c levels at 26 and 52 weeks.
Fixed-Ratio Combination Insulin Glargine-Lixisenatide Didn’t Increase Hypoglycemia
Achieving greater HbA1c reductions with fixed-ratio combination insulin glargine/lixisenatide did not increase rates of hypoglycemia.
Want to read more?
Please login or register first to view this content.
Next post in ADA 75th Scientific Sessions 2015
